Investigations with the electron microscope on peripheral blood of patients with Hodgkin’s disease revealed parallel tubular structures in the cytoplasm of the lymphocytes, similar to those described in the literature. In normal subjects 2–9% of the lymphocytes were found to contain these structures. The number of such lymphocytes is increased in most patients as compared to normals. A correlation between an increase of inclusions containing lymphocytes and the histological or clinical classifications could not be established. An elevation of lymphocytes with tubular structures could be found in both favourable and unfavourable histological and clinical subgroups of Hodgkin patients, but especially in all groups with an unfavourable prognosis. The origin and function of the parallel tubular structures is still unknown, but their increase in lymphocytes of patients with Hodgkin’s disease is of some interest in view of the involvement of these cells.

Keywords:
Hodgkin’s disease, Lymphocyte inclusions, Tubular structures in lymphocytes, Ultrastructure of lymphocytes
This content is only available via PDF.
© 1975 S. Karger AG, Basel
1975
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.